Congenital heart disease: current indications for antithrombotic therapy in pediatric patients.
This report reviews the current status of antithrombotic therapy, including anti-platelet therapy, in pediatric patients with congenital heart disease. The current medications utilized and dose recommendations are emphasized, and indications for their use are reviewed.
Reller
M D
MD
Division of Pediatric Cardiology, Oregon Health Sciences University, 707 SW Gaines Road, CDRC-P, Portland, OR 97201, USA. rellerm@ohsu.edu
D000925:Anticoagulants / Q000627:therapeutic use*; D002648:Child; D004176:Dipyridamole / Q000627:therapeutic use; D018729:Fontan Procedure; D006330:Heart Defects, Congenital / Q000150:complications* / Q000601:surgery; D006350:Heart Valve Prosthesis; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D004176:Dipyridamole; D006493:Heparin